Current status of nephrogenic systemic fibrosis

Clinical Radiology

Volumn 69, Issue 7, 2014, Pages 661-668

  Daftari Besheli, L ^a   Aran, S ^a   Shaqdan, K ^a   Kay, J ^b   Abujudeh, H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; SODIUM THIOSULFATE;

CLINICAL FEATURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; LONG TERM EXPOSURE; NEPHROGENIC SYSTEMIC FIBROSIS; PHOTOTHERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUVA; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; ULTRAVIOLET A RADIATION;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; CYTOKINES; EPIDEMIOLOGIC METHODS; GADOLINIUM; GUIDELINE ADHERENCE; HUMANS; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84901780430     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2014.01.003     Document Type: Review

References (75)

1. T. Grobner Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 2006 1104 1108
2. P. Marckmann, L. Skov, and K. Rossen et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 2006 2359 2362
3. U.S. Food and Drug Administration (2006) A Public Health Advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053112. htm. [accessed 30.01.14].
4. E. Kanal, A.J. Barkovich, and C. Bell et al. ACR guidance document for safe MR practices: 2007 AJR Am J Roentgenol 188 2007 1447 1474
5. European Medicines Agency. Vasovist and nephrogenic systemic fibrosis (NSF). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and- events/news/2009/11/news-detail-000418.jsp&mid=WC0b01ac058004d5c1. [accessed 30.01.14].
6. E. Altun, D.R. Martin, and R. Wertman et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two US universities Radiology 253 2009 689 696
7. H.H. Abujudeh, H. Rolls, and R. Kaewlai et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients J Magn Reson Imaging 30 2009 1335 1340
8. Y. Wang, T.K. Alkasab, and O. Narin et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines Radiology 260 2011 105 111
9. D.R. Martin, S.K. Krishnamoorthy, and B. Kalb et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols J Magn Reson Imaging 31 2010 440 446
10. ACR Manual on Contrast Media. ACR Committee on Drugs and Contrast Media. Available at: http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/ Resources/Contrast%20Manual/2013-Contrast-Media.pdf. [accessed 30.01.14].
11. H.S. Thomsen, S.K. Morcos, and T. Almén et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines Eur Radiol 23 2013 307 318
12. C. Rydahl, H.S. Thomsen, and P. Marckmann High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent Invest Radiol 43 2008 141 144
13. E.A. Sadowski, L.K. Bennett, and M.R. Chan et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 2007 148 157
14. D.J. Todd, A. Kagan, and L.B. Chibnik et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure Arthritis Rheum 56 2007 3433 3441
15. W.M. Shabana, R.H. Cohan, and J.H. Ellis et al. Nephrogenic systemic fibrosis: a report of 29 cases AJR Am J Roentgenol 190 2008 736 741
16. R. Wertman, E. Altun, and D.R. Martin et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities Radiology 248 2008 799 806
17. J. Perez-Rodriguez, S. Lai, and B.D. Ehst et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases Radiology 250 2009 371 377
18. H.H. Abujudeh, R. Kaewlai, and A. Kagan et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients Radiology 253 2009 81 89
19. D.R. Broome, M.S. Girguis, and P.W. Baron et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned AJR Am J Roentgenol 188 2007 586 592
20. M.D. Bridges, B.S. St Amant, and R.B. McNeil et al. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function AJR Am J Roentgenol 192 2009 1538 1543
21. H.S. Thomsen, and P. Marckmann Extracellular Gd-CA: differences in prevalence of NSF Eur J Radiol 66 2008 180 183
22. M.R. Prince, H. Zhang, and M. Morris et al. Incidence of nephrogenic systemic fibrosis at two large medical centers Radiology 248 2008 807 816
23. T.A. Collidge, P.C. Thomson, and P.B. Mark et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort Radiology 245 2007 168 175
24. A.J. Kallen, M.A. Jhung, and S. Cheng et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study Am J Kidney Dis 51 2008 966 975
25. H. Richmond, J. Zwerner, and Y. Kim et al. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis Arch Dermatol 143 2007 1025
26. I. Wahba, E. Simpson, and K. White Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature Am J Transplant 7 2007 2425 2432
27. A.A. Lemy, V. Del Marmol, and A. Kolivras et al. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience J Am Acad Dermatol 63 2010 389 399
28. N.S. Anavekar, A.H. Chong, and R. Norris et al. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient Australas J Dermatol 49 2008 44 47
29. C. Chrysochou, D.L. Buckley, and P. Dark et al. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience J Magn Reson Imaging 29 2009 887 894
30. E. Saussereau, C. Lacroix, and A. Cattaneo et al. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis Forensic Sci Int 176 2008 54 57
31. T. Caccetta, and J.J. Chan Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium Australas J Dermatol 49 2008 48 51
32. A. Rodriguez Jornet, F.J. Andreu Navarro, and R. Orellana Fernandez et al. Gadolinium-induced systemic fibrosis in advanced kidney failure Nefrologia 29 2009 358 363
33. Y. Tsushima, E. Kanal, and H. Thomsen Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases Br J Radiol 83 2010 590 595
34. J.C. Kendrick-Jones, D.M. Voss, and J.R. de Zoysa Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006 Nephrology 16 2011 243 248
35. S. Becker, S. Walter, and O. Witzke et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients Clin Nephrol 73 2010 426 430
36. N.B. Aires, M.N. Sotto, and M. Nico Nephrogenic fibrosing dermopathy: report of two cases Acta Derm Venereol 87 2007 521 524
37. N. Janus, V. Launay-Vacher, and S. Karie et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study Eur J Radiol 73 2010 357 359
38. P. Marckmann An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital Eur J Radiol 66 2008 187 190
39. J.G. Do, Y.B. Kim, and D.G. Lee et al. A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection Ann Rehab Med 36 2012 880 886
40. M. Girardi, J. Kay, and D.M. Elston et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations J Am Acad Dermatol 65 2011 1095 1106 e7
41. S. Sanyal, P. Marckmann, and S. Scherer et al. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis - an autopsy-based review Nephrol Dial Transplant 26 2011 3616 3626
42. J. Kay, H. Bazari, and L.L. Avery et al. Case 6-2008 - A 46-year-old woman with renal failure and stiffness of the joints and skin N Engl J Med 2008 827 838
43. S. Swaminathan, W. High, and J. Ranville et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis Kidney Int 73 2008 1413 1418
44. K. Mathur, S. Morris, and C. Deighan et al. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature J Clin Apheresis 23 2008 144 150
45. K.T. Tran, H.B. Prather, and C.J. Cockerell et al. UV-A1 therapy for nephrogenic systemic fibrosis Arch Dermatol 145 2009 1170
46. M.R. Robinson, S.B. Routhouska, and R.M. Paspulati et al. Alefacept therapy for nephrogenic systemic fibrosis: a case series J Drugs Dermatol 10 2011 922 924
47. D. Kadiyala, D.A. Roer, and M.A. Perazella Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate Am J Kidney Dis 53 2009 133 137
48. T.R. Elmholdt, N. Buus, and M. Ramsing et al. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial J Eur Acad Dermatol Venereol 27 2013 779 784
49. M. Panesar, S. Banerjee, and G.W. Barone Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation Clin Transplant 22 2008 803 808
50. M. Panesar, and R. Yacoub What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Semin Dial 24 2011 373 374
51. M.C. Cuffy, M. Singh, and R. Formica et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature Nephrol Dial Transplant 26 2011 1099 1101
52. Z. Baranyai, Z. Pálinkás, and F. Uggeri et al. Dissociation kinetics of open-chain and macrocyclic gadolinium (iii)-aminopolycarboxylate complexes related to magnetic resonance imaging: catalytic effect of endogenous ligands Chemistry 18 2012 16426 16435
53. S. Swaminathan, T.D. Horn, and D. Pellowski et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization N Engl J Med 357 2007 720 722
54. J. Kimura, T. Ishiguchi, and J. Matsuda et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents Radiat Med 23 2005 322 326
55. W.A. High, R.A. Ayers, and J. Chandler et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis J Am Acad Dermatol 56 2007 21 26
56. T. Chopra, K. Kandukurti, and S. Shah et al. Understanding nephrogenic systemic fibrosis Int J Nephrol 2012 2012 912189
57. P.J. Wermuth, F. Del Galdo, and S.A. Jimenez Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents Arthritis Rheum 60 2009 1508 1518
58. F. Del Galdo, P.J. Wermuth, and S. Addya et al. Jimenez SA NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis Ann Rheum Dis 69 2010 2024 2033
59. P.J. Wermuth, and S.A. Jimenez Gadolinium compounds signaling through tlr 4 and tlr 7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis J Immunol 189 2012 318 327
60. S. Piera-Velazquez, N. Louneva, and J. Fertala et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis Ann Rheum Dis 69 2010 2017 2023
61. K. Bleavins, P. Perone, and M. Naik et al. Stimulation of fibroblast proliferation by insoluble gadolinium salts Biol Trace Elem Res 145 2012 257 267
62. N. Fretellier, J. Idée, and S. Guerret et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis Invest Radiol 46 2011 85 93
63. H. Pietsch, P. Lengsfeld, and T. Steger-Hartmann et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents Invest Radiol 44 2009 226 233
64. US Food and Drug Administration. New warnings required on use of gadonium-based contrast agents. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm225286.htm. [accessed 30.01.14].
65. S.E. Gibson, C.F. Farver, and R.A. Prayson Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature Arch Pathol Lab Med 130 2006 209 212
66. A.S. Boyd, S. Sanyal, and J.L. Abraham Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents J Am Acad Dermatol 59 2008 356 358
67. G.W. White, W.A. Gibby, and M.F. Tweedle Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy Invest Radiol 41 2006 272 278
68. J.B. Othersen, J.C. Maize, and R.F. Woolson et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure Nephrol Dial Transplant 22 2007 3179 3185
69. C.U. Lee, C.M. Wood, and G.K. Hesley et al. Large sample of nephrogenic systemic fibrosis cases from a single institution Arch Dermatol 145 2009 1095
70. A.S. Boyd, J.A. Zic, and J.L. Abraham Gadolinium deposition in nephrogenic fibrosing dermopathy J Am Acad Dermatol 56 2007 27 30
71. R.F. Reilly Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis Clin J Am Soc Nephrol 3 2008 747 751
72. X.T. Lima, M.B. Alora-Palli, and A.B. Kimball et al. Validation of a screening instrument for nephrogenic systemic fibrosis Arthritis Care Res 65 2013 637 642
73. J. Kay, and W.A. High Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis Rheum 58 2008 2543 2548
74. J.H. Distler, A. Jüngel, and L.C. Huber et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis Rheum 56 2007 311 322
75. S. Chandran, J. Petersen, and C. Jacobs et al. Imatinib in the treatment of nephrogenic systemic fibrosis Am J Kidney Dis 53 2009 129 132